Journal profile · Pharmacology & Pharmacy
Current Pharmaceutical Design
ISSN 1381-6128 · eISSN 1873-4286 · Bentham Science Publishers B.V. · NETHERLANDS · Biweekly · Founded 1995
Current Pharmaceutical Design: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.2; subscription journal; median 86 days to acceptance (76 articles, last 24 months); community-reported acceptance: about 25%; 327 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Pharmaceutical Design is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Computational Drug Discovery Methods, Nanoparticle-Based Drug Delivery and RNA Interference and Gene Delivery, together about 24.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Computational Drug Discovery MethodsComputer Science10.8%
- Nanoparticle-Based Drug DeliveryMaterials Science8.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology5.6%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics5.4%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4.8%
- Lipoproteins and Cardiovascular HealthMedicine3.9%
- Tryptophan and brain disordersNeuroscience3.8%
- Synthesis and biological activityChemistry3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.2LetPub ·
- CiteScore 2026-06
- 5.8LetPub ·
- SJR 2026-06
- 0.63LetPub ·
- SNIP 2026-06
- 0.68LetPub ·
- h-index
- 140LetPub ·
- h-index
- 209OpenAlex ·
- i10-index
- 7,345OpenAlex ·
- 2-year mean citedness
- 2.89OpenAlex ·
- Self-citation rate
- 3.1%LetPub ·
- Share of gold OA articles
- 4.5%LetPub ·
Volume
- Articles per year
- 339LetPub ·
Articles by year OpenAlex count · 11,569 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 337 | 4 | 93 |
| 2025 | 327 | 24 | 772 |
| 2024 | 327 | 42 | 1,997 |
| 2023 | 301 | 20 | 2,517 |
| 2022 | 317 | 14 | 3,501 |
| 2021 | 351 | 50 | 3,975 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
86 daysMedian, submission to acceptance · P25–P75 59 days – 112 days
- Acceptance to online
- median 186 days (76 articles)
- Submission to online
- median 284 days
- Sample
- 76 articles with submission and acceptance dates (791 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 25%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Biweekly
- Founded
- 1995
- ISSN
- 1381-6128
- Electronic ISSN
- 1873-4286
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Pharmaceutical Design
What CAS zone is Current Pharmaceutical Design in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Pharmaceutical Design is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Pharmaceutical Design?
The latest impact factor listed by LetPub is 3.2; CiteScore 5.8, h-index 209.
How long does peer review take at Current Pharmaceutical Design?
Based on the dates recorded on 76 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 86 days (interquartile range 59–112 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Pharmaceutical Design?
According to LetPub and DOAJ records, Current Pharmaceutical Design is indexed in SCIE and Scopus.
Is Current Pharmaceutical Design open access, and what is the APC?
Current Pharmaceutical Design is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .